Company / Cost of Revenue
Insulet Corporation Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$768.2M
FY2025
5-year range
$346.7M / $768.2M
FY2021-FY2025
Trend
+22.7%
vs FY2024
Sector context
#53 of 107
Health Care
What the data says
At $768M, Insulet Corporation's cost of revenue ranks #55 of 107 in the Health Care sector. Cost of Revenue has increased for 9 consecutive years, from $156M in FY2016 to $768M in FY2025.
Based on SEC 10-K filings.
$768M in FY2025 with a 5-year CAGR of +19.0%.
Increased from $537M to $768M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +15.4%
- 5-Year CAGR
- +19.0%
- 10-Year CAGR
- -
Sector benchmark
#55 of 107 in Health CareTop 50% of 107This company $768.2M Sector average $11.8B
▼
-93.5% below sector average
Key checks
Key Insights
- Insulet Corporation's cost of revenue has grown for 9 consecutive years.
- 5-year CAGR of +19.0%, indicating consistent growth.
- In FY2025, cost of revenue increased 22.7% year-over-year.
- Ranks #53 out of 107 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 20.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $768.2M | +22.7% |
| FY2024 | $625.9M | +16.5% |
| FY2023 | $537.2M | +7.5% |
| FY2022 | $499.7M | +44.1% |
| FY2021 | $346.7M | +7.6% |
| FY2020 | $322.1M | +24.9% |
| FY2019 | $257.9M | +33.2% |
| FY2018 | $193.6M | +3.8% |
| FY2017 | $186.6M | +19.7% |
| FY2016 | $155.9M | +19.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026